Panel discussion - Redefining the speed of innovation
Information
- Industry actors and regulators managed to speed the development and approval time of the COVID-19 vaccine. Is it possible – and desirable – to maintain this momentum under more normal circumstances? Do we have the right priorities when it comes which pharma products are fast-tracked?
- Should the industry and regulators rethink how we approach clinical trials and what would that entail? What impact would new technologies play in that regard?
- What has the pandemic taught us about using Real World Data (RWD)? Does it hold the potential to revolutionize the way new drugs are tout on the market?
- How much does speed rely on stronger cooperation between researchers, public and industry actors? Can HERA find the right formula?
Speakers
Marco Cavaleri
head of biological health threats and vaccine strategyEuropean Medicines AgencySusan Forda
vice president Global Regulatory AffairsLilly Peter Marks
director - Center for Biologics Evaluation and Research U.S. Food and Drug Administration Patrick Bertrand
founder and directorGlobal Health AdvocatesHC
Helen Collis
ReporterPolitico EuropeRegistered attendees
FB
Francesco Bordone
European Commission